Michael A. Fremed

Michael A. Fremed

Auto-generated profile, based on publicly available information

Michael A. Fremed

Columbia University Irving Medical Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MLMatthew J. Lewis
Matthew J. Lewis
BABrett R. Anderson
Brett R. Anderson
MFMichael Fremed
Michael Fremed
MAMelissa Argenio
Melissa Argenio
Usha KrishnanUsha Krishnan
Usha Krishnan
JWJoyce Woo
Joyce Woo
Background: We sought to assess the impact and predictors of coronavirus disease 2019 (COVID‐19) infection and severity in a cohort of patients with congenital heart disease (CHD) at a large CHD center in New York City. Methods and Results: We performed a retrospective review of all individuals with CHD followed at Columbia University Irving Medical Center who were diagnosed with COVID‐19 between March 1, 2020 and July 1, 2020. The primary end point was moderate/severe response to COVID‐19 infection defined as (1) death during COVID‐19 infection; or (2) need for hospitalization and/or respiratory support secondary to COVID‐19 infection. Among 53 COVID‐19‐positive patients with CHD, 10 (19%) were <18 years of age (median age 34 years of age). Thirty‐one (58%) had complex congenital anatomy including 10 (19%) with a Fontan repair. Eight (15%) had a genetic syndrome, 6 (11%) had pulmonary hypertension, and 9 (17%) were obese. Among adults, 18 (41%) were physiologic class C or D. For the entire cohort, 9 (17%) had a moderate/severe infection, including 3 deaths (6%). After correcting for multiple comparisons, the presence of a genetic syndrome (odds ratio [OR], 35.82; P =0.0002), and in adults, physiological Stage C or D (OR, 19.38; P =0.002) were significantly associated with moderate/severe infection. Conclusions: At our CHD center, the number of symptomatic patients with COVID‐19 was relatively low. Patients with CHD with a genetic syndrome and adults at advanced physiological stage were at highest risk for moderate/severe infection.

1 April 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
MFMichael A. Fremed
Michael A. Fremed
KFKanwal M. Farooqi
Kanwal M. Farooqi
The acute manifestations and short-term outcomes of multisystem inflammatory syndrome (MIS-C) have been extensively described; however, our understanding of the longitudinal outcomes associated with this condition continue to evolve. Here we review the existing literature on outcomes of MIS-C up to 1 year following diagnosis and summarize current published expert recommendations for management and follow up of these patients.

22 December 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
UKUtkarsh Kohli
Utkarsh Kohli
LDLavina Desai
Lavina Desai
DCDevyani Chowdhury
Devyani Chowdhury
AHAshraf S. Harahsheh
Ashraf S. Harahsheh
AYAlexandra B. Yonts
Alexandra B. Yonts
JAJocelyn Y. Ang
Jocelyn Y. Ang

28 January 2022 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
MFMichael A. Fremed
Michael A. Fremed
EHEmma W. Healy
Emma W. Healy
NCNak Hyun Choi
Nak Hyun Choi
ECEva W. Cheung
Eva W. Cheung
TCTarif A. Choudhury
Tarif A. Choudhury
TSThomas J. Starc
Thomas J. Starc
Cardiac involvement associated with multi-system inflammatory syndrome in children (MIS-C) has been extensively reported, but the prevalence of cardiac involvement in children with SARS-CoV-2 infection in the absence of inflammatory syndrome has not been well described. In this retrospective, single center, cohort study, we describe the cardiac involvement found in this population and report on outcomes of patients with and without elevated cardiac biomarkers. Those with MIS-C, cardiomyopathy, or complex congenital heart disease were excluded. Inclusion criteria were met by 80 patients during the initial peak of the pandemic at our institution. High-sensitivity troponin T and/or NT-proBNP were measured in 27/80 (34%) patients and abnormalities were present in 5/27 (19%), all of whom had underlying comorbidities. Advanced respiratory support was required in all patients with elevated cardiac biomarkers. Electrocardiographic abnormalities were identified in 14/38 (37%) studies. Echocardiograms were performed on 7/80 subjects, and none demonstrated left ventricular dysfunction. Larger studies to determine the true extent of cardiac involvement in children with COVID-19 would be useful to guide recommendations for standard workup and management.

2 July 2020 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
MFMichael A. Fremed
Michael A. Fremed
ILIrene D. Lytrivi
Irene D. Lytrivi
LLLeonardo Liberman
Leonardo Liberman
BABrett R. Anderson
Brett R. Anderson
OBOliver M. Barry
Oliver M. Barry
TSThomas J. Starc
Thomas J. Starc
Approximately, 1.7 million individuals in the United States have been infected with SARS-CoV-2, the virus responsible for the novel coronavirus disease-2019 (COVID-19). This has disproportionately impacted adults, but many children have been infected and hospitalised as well. To date, there is not much information published addressing the cardiac workup and monitoring of children with COVID-19. Here, we share the approach to the cardiac workup and monitoring utilised at a large congenital heart centre in New York City, the epicentre of the COVID-19 pandemic in the United States.

3 August 2020 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
NCNak Hyun Choi
Nak Hyun Choi
ESEric S. Silver
Eric S. Silver
MFMichael Fremed
Michael Fremed
LLLeonardo Liberman
Leonardo Liberman
A diagnosis of Brugada pattern in paediatric or adolescent patients is rare. COVID-19 is characterised by fevers and a pro-inflammatory state, which may serve as inciting factors for Brugada pattern. Recently described in two adult patients, we report the first case of Brugada pattern in an adolescent with COVID-19.